DDX20. also known as Gemin3 or DP103. is a member of the DEAD-box family of RNA helicases, which play essential roles in RNA metabolism, including transcription, splicing, and translation. This ATP-dependent enzyme is a core component of the survival motor neuron (SMN) complex, involved in spliceosomal small nuclear ribonucleoprotein (snRNP) assembly and pre-mRNA processing. DDX20 also interacts with viral proteins, such as HIV-1 Rev, and participates in innate immunity by regulating type I interferon signaling.
Antibodies targeting DDX20 are critical tools for studying its function in RNA biology, viral pathogenesis, and disease mechanisms. They are widely used in techniques like Western blotting, immunoprecipitation, immunofluorescence, and chromatin immunoprecipitation (ChIP) to detect DDX20 expression, localization, and protein interactions. Dysregulation of DDX20 has been implicated in cancers (e.g., breast cancer, hepatocellular carcinoma) and neurological disorders like spinal muscular atrophy (SMA), where SMN complex dysfunction occurs. Researchers also explore its role in autoimmune diseases and viral infections, including HIV and hepatitis C.
Commercially available DDX20 antibodies are typically raised in rabbits or mice, with validation across multiple applications and species (human, mouse, rat). Specificity is confirmed via knockout controls or siRNA knockdown. These reagents support investigations into DDX20’s dual roles as a helicase and a transcriptional co-regulator, particularly its interaction with transcription factors like ETS-1 or MYC in oncogenesis.